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Abstract
Despite the introduction of screening and, latterly, vaccination programs in the developed world, globally cervical
cancer remains a significant health problem. For those diagnosed with advanced or recurrent disease even within
resource rich communities, prognosis remains poor with an overall survival (OS) of just over 12 months. New
therapeutic interventions are urgently required. Advances in our understanding of the mechanisms underlying
tumor growth and the downstream effects of human papilloma virus (HPV) infection identified angiogenesis
as a rational target for therapeutic intervention in cervical cancer. Anti-angiogenic agents showed promising
activity in early phase clinical trials culminating in a randomized phase III study of the humanized monoclonal
antibody to vascular endothelial growth factor (VEGF), bevacizumab, in combination with chemotherapy. This
pivotal study, the Gynecologic Oncology Group protocol 240, met its primary endpoint demonstrating a significant
improvement in OS. Bevacizumab became the first targeted agent to be granted regulatory approval by the United
States Food and Drug Administration for use alongside chemotherapy in adults with persistent, recurrent or metastatic
carcinoma of the cervix. This review outlines the rationale for targeting angiogenesis in cervical cancer focusing on the
current indications for the use of bevacizumab in this disease and future directions.
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Introduction
Following the introduction of population based screen-
ing, the incidence of cervical cancer has been declining
in the developed world a trend that is expected to con-
tinue with the increased availability and implementa-
tion of HPV vaccination programs. Globally, however,
cervical cancer remains a major health issue and is the
third most common cancer affecting women with 85 %
of the diagnoses and 88 % of deaths due to this disease
occurring in resource poor regions of the world [1].
Even within the United States (US), despite the avail-
ability of screening programs, in 2015 over 12,000
women will be diagnosed with cervical cancer with ap-
proximately 4000 women expected to die from their dis-
ease. Furthermore, between 2000 and 2012 the proportion
of women diagnosed with stage IV cervical cancer in the
US rose [2]. Advanced cervical cancer disproportionately
affects women from lower socio-economic groups, those
who are under or uninsured, women of African American
or Hispanic ethnicity and those from medically under-
served communities [3].
Early-stage cervical cancer is a potentially curable
disease either by surgery (for those diagnosed with
International Federation of Gynecology and Obstetrics
(FIGO) stage IA/B1 disease) or by a combination of
low dose chemotherapy administered concurrently with
radiotherapy followed by intracavitary brachytherapy. For
those not suitable for local control, who recur or who are
diagnosed with metastatic disease outcomes are poor with
5-year survival rates between 5 and 15 % [4]. In this
setting any treatment is palliative and the goals of care are
to prolong survival but also, and perhaps more import-
antly, to maintain and/or improve quality of life (QoL). A
number of first line, cisplatin based, doublet, combination
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chemotherapy regimens have been investigated in pro-
spective randomized clinical trials conducted by the Gyne-
cologic Oncology Group (GOG). These culminated in
GOG 204, a four-arm study that compared cisplatin in
combination with paclitaxel, vinorelbine, gemcitabine or
topotecan [5]. Outcomes were similar in all arms with a
non-significant trend in favor of cisplatin/paclitaxel (over-
all survival (OS) 12.9 months) compared to the other
three arms (OS 10–10.3 months) and similar overall re-
sponse rates (ORR). In a further randomized phase III
clinical trial conducted by the Japanese GOG (JGOG)
carboplatin in combination with paclitaxel was found to
be non-inferior to cisplatin/paclitaxel [6]. For women with
poor prognostic features including poor performance sta-
tus, prior treatment with chemoradiation or recurrence
within 1 year, response duration can be short at less than
6 months in some cases. Response to treatment is also
influenced by the site of recurrence with disease con-
trol in previously irradiated areas proving particularly
challenging [7]. There are no standard of care second
line options for these women when their cancer pro-
gresses. New therapeutic approaches are, therefore, ur-
gently required. However, the cervical cancer patient
demographic also poses unique challenges in terms of
sustainable drug development where cost effectiveness
and access to new treatments for those in need are key
issues. Furthermore, conducting clinical trials in this
patient group can also pose difficulties as women diag-
nosed with advanced cervical cancer frequently come
from sections of society where, historically, engagement
in clinical research has been low.
Targeting angiogenesis is one of the most promising
therapeutic strategies to emerge in recent years in the
treatment of cervical cancer. Angiogenesis is a critical
process in cervical carcinogenesis and tumor progres-
sion. Following the publication in 2014 of the random-
ized phase III study GOG 240, the US Food and Drug
Administration (FDA) approved the first anti-angiogenic
agent, bevacizumab (Avastin, Genentech/Roche), in com-
bination with chemotherapy for use in women with ad-
vanced cervical cancer [8]. This article will review the
rationale for studying anti-angiogenic therapy in cervical
cancer, focus on the clinical use of bevacizumab and
finally highlight potential future directions.
Review
Angiogenesis in cervical cancer and rationale for targeting
Angiogenesis
Angiogenesis is a physiologic and highly ordered process
that involves the regulation of multiple signaling pathways
and requiring interaction between different cell types, in-
cluding endothelial cells, stromal cells (fibroblasts), and
their interaction with the extracellular matrix, cytokines
and growth factors, which leads to the effective formation
of new blood vessels. Hypoxia and the mechanisms that
mediate hypoxic response are key drivers of physiologic
angiogenesis. Under hypoxic conditions expression of
hypoxia inducible factor, (HIF- 1α) is induced in endothe-
lial cells, resulting in VEGF-A, and vascular endothelial
growth factor receptor 2 (VEGFR-2) expression [9]. Al-
though numerous proangiogenic factors have been de-
scribed there is universal agreement that the VEGF family
of ligands, (VEGF-A, to -D and placental growth factor
[PLGF]) and their associated receptor tyrosine kinases
(VEGFR)-1, 2 and 3 are the most important regulators of
angiogenesis. VEGF-A, usually referred to as VEGF, binds
to VEGFR-1 and VEGFR-2; the stimulation of endothelial
cell mitogenesis and vascular permeability is mediated
by its interaction with VEGFR-2 [10]. PLGF and VEGF-
B selectively bind to VEGFR-1 and stimulate vessel
growth and maturation and recruit proangiogenic bone
marrow-derived progenitors [11, 12]. VEGF-C and
VEGF-D primarily interact with VEGFR-3 stimulating
lymphangiogenesis [13]. Other crucial steps in physio-
logic angiogenesis involve the recruitment of pericytes.
Pericytes, recruited primarily by platelet-derived growth
factor (PDGF), secreted by endothelial cells, are essen-
tial for the stabilization, maturation and support of new
vessels [14]. Angiopoietins (Angs) 1 and 2 are expressed
on the surface of pericytes and are ligands of the endo-
thelial cell receptor Tie-2. Thus, the angiopoietin/Tie
pathway is involved in the stability of mature vessels and
proliferation of endothelial cells. However, the contribu-
tion of Ang-1 and Ang-2 to the angiogenesis process is
distinct. Ang-1 functions as a Tie2 receptor agonist when
it binds to TIE-2 receptors expressed on the surface of
endothelial cells, maintaining the integrity of existing ves-
sels. In contrast, Ang-2 is mainly secreted by endothelial
cells at sites of active vascular remodeling. Ang-2 acts an-
tagonistically to Ang1, promoting sprouting angiogenesis
facilitating the effects of VEGF [15, 16], whilst VEGF also
upregulates Ang-2 in endothelial cells [17].
Many cancers exploit aberrant angiogenic mecha-
nisms to stimulate tumor growth and metastasis. Tumor
angiogenesis was established as a potentially attractive
therapeutic target for the treatment of cancer with the
publication of Folkman’s hypothesis in 1971 [18]. Angio-
genesis is required for tumor growth beyond 1-2 mm3,
when the tumor demand for oxygen and nutrients sur-
passes the local supply and the hypoxic microenviron-
ment, through the expression of HIFs leads to the
activation of angiogenesis. Tumor related angiogenesis, in
contrast to physiologic angiogenesis, leads to a more dis-
organized vasculature, which is also more permeable, lim-
iting the delivery of drugs to tumor cells. Anti-angiogenic
agents have been shown to transiently ‘normalize’ the
tumor vasculature, resulting in an increased delivery of
oxygen and drugs into the tumor microenvironment [19].
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Many cancers induce VEGF-A expression promoting the
formation of new tumor blood vessels, rapid tumor
growth, and facilitation of metastatic potential [20]. Other
mechanisms also contribute to tumor related angiogen-
esis, such as overexpression of VEGF receptors, especially
VEGFR-1. Several multi-target tyrosine-kinase inhibitors
(TKIs) of VEGFR have recently been evaluated showing
encouraging results [21]. In addition, constitutive activa-
tion in a number of oncogenes such as ras, PI3k and src,
or the loss of tumor suppressor function, for example
through mutations in the tumor suppressor gene von
Hippel Lindau which enhances the activity of HIF1α, have
the capacity to induce proangiogenic factors and growth
factors, promoting tumor angiogenesis [22–24].
VEGF-A potentiates proliferation of endothelial cells
by activating the C-Raf-MAPK/ERK kinase signaling
pathway [25]. Furthermore, there is interplay between
other proangiogenic pathways, which are upregulated in
tumors. These include Angs, fibroblast growth factor
(FGF)/fibroblast growth factor receptor (FGFR), PDGF/
platelet-derived growth factor receptor (PDGFR), hep-
atocyte growth factor (HGF)/MET and the PI3K/Akt/
mTOR signaling pathways. The Ang–TIE2 pathway is of
particular interest, as Ang-1 and 2 are upregulated in
many cancer subtypes. Research on this signaling system
has also provided evidence on the role of pericyte cells,
which secrete ang-1 and express PDGF receptors, and
explains the anti angiogenic action of some of the multi-
targeted TKI inhibitors [26, 27]. The PDGF family con-
sists of PDGF-A to -D polypeptide homodimers and the
PDGF-AB heterodimer ligands and their binding tyrosine
kinase receptors, PDGFR-α and –β. Aberrant activation of
this pathway is implicated in pericyte recruitment to ves-
sels; secretion of proangiogenic factors; stimulation of
endothelial cell proliferation, and promotion of lymphan-
giogenesis among others [28]. The FGF/FGFR family com-
promises a total of 23 members, 18 of which function as
ligands for four receptor tyrosine kinases (FGFR-1 to −4),
regulating normal cell growth and differentiation and
angiogenesis [29]. Overexpression of FGF, mainly FGF1
and FGF2, and FGFR contribute to different mechanisms,
such as activating mutations, gene amplification and
translocations, among others, leading to enhanced angio-
genesis through the stimulation and release of other
proangiogenic factors [30]. In addition, a collaborative
interplay between FGF and VEGF signaling has also been
demonstrated to be important for angiogenic and meta-
static processes [31]. The inhibition of these alternate
pathways (PDGF, FGF) may mediate resistance and po-
tentiate VEGF inhibition, supporting a multitargeted ap-
proach inhibiting both VEGFR and PDGFR [32]. The
HGF/MET binding also mediates tumor angiogenesis and
growth in a variety of epithelial malignancies. The HGF/
MET axis is responsible for the cell-scattering phenotype
and increases angiogenesis by direct activation of
endothelial cells or via downstream stimulation of
pro-angiogenic pathways, including PI3K/Akt and Src
and production of proangiogenic factors, such as
VEGF [33–35]. The PI3K/Akt/mTOR cascade is also
involved in angiogenesis through the interaction of the
mTOR complex 1 and 2 with the VEGF pathway, and
moreover, Akt has shown importance for endothelial
cell survival [36, 37].
Greater understanding of these pathways continues to
provide valuable insights into the molecular mechanisms
that underlie tumor angiogenesis and provide a founda-
tion for the development of novel anti-angiogenic thera-
peutic strategies.
Angiogenesis in cervical cancer
High-risk HPV subtypes 16 and 18 (although other
subtypes have also been implicated) are responsible
for approximately 70 % of invasive cervical cancers
[38]. Emerging data suggest that viral integration into
the host cell genome results in overexpression of a
number of host genes, which are potential drivers of
carcinogenesis [39]. However, the HPV oncoproteins
E5, E6, and E7 are the primary viral factors respon-
sible for initiation and progression of cervical cancer.
E6, E7 and to a lesser extent E5 play key roles in up-
regulating angiogenesis through the VEGF pathway
through their effects on p53 degradation, HIF-1α and
inactivation of retinoblastoma protein (pRb). HPV E6
promotes p53 ubiquitination and degradation after
E6-p53 binding. Degradation of p53 promotes angio-
genesis by down regulating thrombospondin-1 and by
increased production of VEGF. HPV E7 results in ab-
rogation of pRb function resulting in p21-RB pathway
dysregulation thereby increasing VEGF. In addition,
HPV E6 (in a p53 independent manner) and E7 also
enhance the induction of HIF-1α, thus increasing
VEGF through a second mechanism [40–43] (Fig. 1).
Over the past decade, the relationship between HPV-
16 and 18 associated cervical tumors, hypoxia, markers
of tumor angiogenesis and prognosis has emerged. Initial
descriptions of high risk HPV related premalignant cer-
vical lesions seen on colposcopy included atypical angio-
genic proliferation along the basement membrane and
suggested a role for angiogenesis in the transition from
premalignant lesions to invasive cervical carcinoma.
Microvessel density (MVD) has been reported to in-
crease with the grade of pre-malignant lesions [44]. High
intratumoral microvessel density (MVD) in cervical can-
cer has been associated with poorer prognosis, advanced
stage at presentation, and greater risk of nodal involve-
ment [45]. However, this data is controversial with some
studies showing a poor prognosis, others a better prog-
nosis and some no effect on outcome. In an analysis
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performed on tumor specimens from the phase III
study GOG 109 [45], which investigated the addition of
cisplatin chemotherapy to adjuvant radiation following
radical hysterectomy, MVD was an independent prog-
nostic marker for improved progression-free survival
(PFS) and OS [hazard ratio (HR) = 0.36, 95 % CI: 0.17–0.79,
p = 0.010]. In an ad hoc analysis of GOG 109 [46], speci-
mens were assessed for expression of markers of tumor
angiogenesis including VEGF, TSP-1 (anti-angiogenesis
factor), cluster of differentiation 31 (CD31) and CD105
(tumor-specific endothelial marker). CD31 was used in
the GOG 109 analysis to measure MVD and predicted
for a good outcome. In contrast, the presence of
CD105-positive vessels in cervical cancer samples has
shown an association with risk of lymph node metasta-
sis, and worse PFS and OS [47]. The differences in out-
come observed in these studies may relate to the
method used to study MVD. Some markers such as
CD31, used in GOG109, may reflect “good angiogenesis”,
with CD31 positive endothelial cells exhibiting organized
vasculature, potentially leading to well vascularized and
oxygenated tumors, leading to better outcomes, whilst
other markers such as CD105 may indicate a more disor-
dered endothelial structure resulting in poorer outcomes.
In addition, analysis of VEGF has shown increased VEGF
expression in cervical intraepithelial neoplasia grade III
and squamous cell carcinoma when compared with con-
trol cervical tissue. In the cervical cancer samples higher
VEGF levels were associated with advanced stage disease,
increase risk of nodal metastasis, and worse PFS and OS
[48]. In cervical carcinomas, elevated serum VEGF has
been identified as a poor prognostic factor [49, 50].
Angiogenesis plays a pivotal role, not only in initiation
of cervical cancer, but also in proliferation and progres-
sion of the disease, hence targeting angiogenesis has
emerged as a rational therapeutic approach.
Bevacizumab in advanced and recurrent cervical cancer
Improving the limited success achieved with traditional
cytotoxic chemotherapy in patients with recurrent and
metastatic cervical cancer represents a critical unmet
medical need. Metastatic cervical cancer patients present
a number of challenges including: disease related com-
plications (obstructive uropathy, bleeding); impact of
prior therapies (particularly when recurrence occurs in a
previously irradiated field), poor performance status and
frequent psychosocial issues.
Bevacizumab is a recombinant humanized monoclonal
IgG1 antibody directed against VEGF-A which blocks
signal transduction through VEGFR-1 and 2 associated
pathways. In preclinical models bevacizumab suppressed
VEGF-induced tumor growth and reduced tumor MVD.
Bevacizumab appeared to normalize primitive tumor
vasculature, leading to an increase in tumor oxygenation
and potentially enhancing delivery of cytotoxic agents
thereby potentiating their efficacy [51]. Bevacizumab has
shown clinical activity in different solid tumor types
resulting in approval by the FDA for treatment of meta-
static colorectal cancer, non-small cell lung cancer, renal
cell carcinoma, glioblastoma multiforme and ovarian
cancer (Fig. 2).
Wright and colleagues initially reported the clinical
utility of bevacizumab in the treatment of persistent or
recurrent cervical cancer patients. This small retrospect-
ive analysis showed a meaningful clinical benefit rate of
67 % in a heavily pretreated patient population (median
of 3 prior regimens), when bevacizumab was combined
with chemotherapy [52]. These results catalyzed a phase
II trial conducted by the GOG (GOG 227C), which
aimed to determine the efficacy and toxicity profile of
single agent bevacizumab in advanced cervical cancer
patients. This study demonstrated encouraging clinical
activity which compared favorably with historical single
Fig. 1 Tumor Hypoxia and Viral Oncogenes Drive Angiogenesis. Abbreviations: HPV: Human papillomavirus; pRb: retinoblastoma gene product;
HDAC1, 4, 7: Histone deacetylases 1, 4, 7; TSP-1: Thrombospondin-1; HIF-1α: hypoxia-inducible factor 1 alpha; VEGF: Vascular endothelial growth factor
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agent cytotoxic phase II studies in similar previously
treated patient populations [53]. Among 46 evaluable pa-
tients, the ORR was 11 %, with median response duration
of 6.21 months (range, 2.83 to 8.28 months), and a median
PFS and OS of 3.4 months (95 % CI: 2.53–4.53 months)
and 7.3 months (95 % CI, 6.11–10.41 months), respect-
ively. The 6-month PFS rate was 24 %. In this study, al-
most 83 % of patients had received prior pelvic radiation
and 74 % had received at least one prior cytotoxic regimen
for recurrent disease (74 %). Bevacizumab was generally
well tolerated, fistula occurring in only 2.17 % of patients.
Following on from GOG 227C, the combination of beva-
cizumab with platinum-based chemotherapy was investi-
gated in a further phase II clinical trial. Twenty seven
women undergoing first line treatment for locally advanced
or recurrent disease received bevacizumab 15 mg/kg
combined with cisplatin and topotecan administered on
a 21-day cycle. Although the results in median PFS and
OS were encouraging (7.1 months and 13.2 months re-
spectively), the toxicity reported from the combination
was significant with grade 3–4 hematologic toxicity being
common (thrombocytopenia 82 %, anemia 63 %, and neu-
tropenia 56 %) and a significant fistula rate of 26 % [54].
Following on from the promising activity observed in
early phase clinical trials, a four-arm prospective, ran-
domized clinical trial, GOG 240, was conducted. The
aim of GOG 240 was to demonstrate whether the
addition of bevacizumab to chemotherapy lead to an im-
provement in OS. In addition ORR, PFS, toxicity and
health related Quality of Life (HR QoL) end points were
also explored. GOG 240 had a 2 × 2 factorial study de-
sign that involved randomization to both the standard
cisplatin and paclitaxel arm and to a non-platinum con-
taining regimen, paclitaxel and topotecan, with or with-
out Bevacizumab 15 mg/kg intravenously every 21 days
(Fig. 3). In the modern era, exploration of a non-
platinum based combination was of interest as many
patients receive cisplatin in combination with radio-
therapy for their definitive frontline treatment; hence
cisplatin may be less effective than previously reported
following the introduction of chemotheradiotherapy as
a standard of care. Stratification factors included stage
IVB vs. recurrent/persistent disease, PS 0–1 and prior
concomitant Cisplatin and radiation. Treatment was
continued until disease progression (PD), unaccept-
able toxicity or complete response (CR). In addition,
archival diagnostic tissue was collected for correlative
studies.
GOG 240 was activated on April 9, 2009 reaching
target accrual on January 2, 2012, for a total of 452
patients. Sample size calculation was based on in-
creasing the median OS from 12 to 16 months, de-
tecting with 90 % power, a reduction in the risk of
death of at least 30 %, with the one-sided type I error
rate limited to 2.5 % for each regimen. Over 220 pa-
tients were treated with each of the chemotherapy
backbones (225 chemotherapy alone, 227 chemother-
apy plus bevacizumab). Clinical characteristics were
well distributed between groups receiving the 2 back-
bones: median age of enrolled patients was 49 years;
the majority of patients had squamous cell cancer
(70 %) with 20 % having adenocarcinomas. The ma-
jority of patients had recurrent disease (73 % chemo-
therapy arm and 70 % chemotherapy plus bevacizumab
arm). The rate of persistent disease was 11 % in both arms
and 16 % of patients in each arm presented with advanced
disease at diagnosis. The proportion of prior platinum
chemotherapy in combination with radiotherapy was also
well-balanced between each arm (74 % and 75 % in the
chemotherapy and the investigational arm respectively,
p = 0.666). 55 % of patients had locally recurrent pelvic
disease after chemoradiotherapy. Notably, the majority
of patients in each chemotherapy group had a PS of 0
(PS 0–1 required for enrollment).
Fig. 2 Indications granted FDA regulatory approval for Bevacizumab for solid tumors treatment. Abbreviations: VEGF-A: vascular endothelial
growth factor; IND: Investigational New Drug Application; NSCLC: non-small cell lung cancer; BC: breast cancer; RCC: renal carcinoma; CRC:
colorectal cancer; OC: ovarian cancer
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A pre-planned interim analysis after 174 deaths to de-
termine futility/superiority was conducted on February
6, 2012 and presented at the Society of Gynecologic
Oncology (SGO) meeting in 2013 [55]. This demon-
strated that the topotecan-paclitaxel arm was not superior
or inferior to the cisplatin-paclitaxel arm (median OS 15
vs. 12.5 months respectively, HR 1.20; 95 % CI: 0.82–1.76).
Following a second analysis, with a median follow-up of
20.8 months the National Cancer Institute’s (NCI) Data
Safety Monitoring Board (DSMB) recommended ending
the trial and also, due to the data’s potential to alter the
standard of care, that the results were released into the
public domain [56]. The study demonstrated a signifi-
cant improvement in OS for the addition of bevacizu-
mab to chemotherapy compared to chemotherapy alone
(17 months versus 13.3 months respectively; HR = 0.71;
95 % CI: 0.54–0.95; p = 0.0035). In addition, the benefit of
bevacizumab was reported for both chemotherapy regi-
mens—cisplatin-paclitaxel ± bevacizumab median OS 14.3
vs. 17.5 months (p = 0.03) and topotecan-paclitaxel ± beva-
cizumab-median OS 12.7 vs. 16.2 months (p = 0.08). The
median PFS in the bevacizumab group was 8.2 months
compared with 5.9 months in the chemotherapy alone
group (HR 0.67; 95 % CI, 0.54–0.82; p = 0.0002). Response
rate also was higher in the bevacizumab group 48 vs. 36 %
(p = 0.008). The exploratory subgroup analysis suggested
that the effect of bevacizumab was consistent across
multiple prognostic subgroups, and that prior platinum
exposure or recurrent disease in the pelvis after prior
radiation did not preclude benefit from bevacizumab.
These data, published in the New England Journal of
Medicine [57], represented the first time a targeted
agent showed improvement in OS in patients with cer-
vical cancer. Recent planned subgroup analyses presented
in abstract form only, suggested that the addition of beva-
cizumab was associated with a greater likelihood of CR
within the irradiated pelvis (61 %, N = 11) compared to
chemo alone (39 %, N = 7), and that achieving CR (44/452
patients (9.7 %) is associated with prolonged OS (OS
39.3 months while median OS for patients with CR
on the cisplatin–paclitaxel–bevacizumab arm has not
been reached) [58]. Previously described poor prog-
nostic factors including African American ethnicity,
PS, measureable disease within the pelvis, prior cisplatin,
and short progression-free interval were also prognostic in
GOG 240. However, the investigators questioned their
utility at guiding whether to add bevacizumab as high-risk
patients did appear to benefit [59].
The addition of bevacizumab to chemotherapy did,
however, result in increased toxicity, notably; increased
risk of fıstula formation and perforation of the gastrointes-
tinal and genitourinary tracts (10.9 vs. 1 %, p = 0.002),
grade 2 hypertension (25 vs. 2 %, p < 0.001), grade 4 neu-
tropenia (35 vs. 26 %, p = 0.04), and thromboembolism (8
vs. 1 %, p = 0.001). Gastrointestinal and genitourinary
bleeding grade 3–4 was uncommon (2 % vs <1 %, p = 0.37
Fig. 3 GOG 240 study design. Abbreviations: GOG, Gynecologic Oncology Group; PS, performance status; m2: square meters, mg: milligram, IV:
intravenous, Kg: kilogram. Figure 3 is from I. Diaz-Padilla et al. Critical Reviews in Oncology/Hematology 85 (2013) 303–314 [77] and is used with permission
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and 3 % vs <1 %, p = 0.12, respectively), and clinically
relevant central nervous system bleeding did not occur.
Fistulae and perforations appeared to occur exclusively
in patients who had undergone prior pelvic radiother-
apy (reported in abstract form only) [60]. A better un-
derstanding of patients at risk is required if we are to
minimize fistula/perforation rates in the clinic and ad-
equately advise patients regarding the level of risk. In
addition, although differences in HRQoL, assessed using
the Functional Assessment of Cancer Therapy—Cervix
Trial Outcome Index scale (FACT-Cx TOI scale), did not
reach statistical significance on average HRQoL was 1.2
points lower in the bevacizumab containing treatment
arm (99 % CI, −4.1 to 1.7; p = 0.30) [61].
On August 14, 2014, under the FDA Priority Review pro-
gram [62] bevacizumab in combination with chemotherapy
(both study arms) was granted regulatory approval in the
US for treatment of cervical cancer. Following the FDA
approval, the National Comprehensive Cancer Network
(NCCN) upgraded cisplatin-paclitaxel-bevacizumab to cat-
egory 1 in August 2014 and listed topotecan-paclitaxel-
bevacizumab as category 1 in September 2014 [63]. The
final analysis from GOG 240 has confirmed that benefits
obtained from the addition of bevacizumab are sus-
tained after 348 events and with a median follow-up
of 50 months; bevacizumab-containing regimens con-
tinue to demonstrate a significant improvement in OS
over chemotherapy alone: 16.8 vs 13.3 months (HR
0.765, 95 % CI: 0.62, 0.95;p = 0.0068) [64]. However,
survival in the control arms of GOG240 was greater
than in previous studies and potentially reflects the
higher PS of the clinical trial patient population. How
outcome and toxicity translate in the broader non trial pa-
tient population is awaited a further area where “real
world data” will better inform future clinical practice.
Whilst the data from GOG 240 resulted in a change to
the standard of care not all women benefited and that
benefit was relatively short lived. Identification of pre-
dictive biomarkers both for response and for toxicity is
desirable if we are to optimize the use of this drug. Ini-
tial reports from correlative studies evaluated the impact
of pretreatment circulating tumor cells (CTCs) on OS
showing a correlation between high pretreatment CTC
counts, and greater declines of CTC during treatment,
with lower risk of death (HR 0.87; 95 % CI 0.79, 0.95)
upon addition of bevacizumab [65]. Data from this and
from other correlative studies are required and valid-
ation is essential if predictive biomarkers are to become
clinically useful. There are potentially opportunities to
explore predictive biomarkers across tumor types and
data sets which may benefit a larger number of patients,
particularly in relation to prediction of toxicity.
Whilst the addition of bevacizumab to chemotherapy
has become a new standard of care for women in resource
rich communities it remains inaccessible to those at great-
est need. The cost implications and generalizability of in-
corporating bevacizumab in poorly resourced countries
and communities is a significant issue, however questions
around cost-effectiveness have also risen even in resource
rich regions. An initial cost-effectiveness analysis reported
by Phippen et al. showed an incremental cost-effectiveness
ratio (ICER) of $155 K/quality adjusted life year (QALY)
[66]. However, an updated analysis using a Markov deci-
sion tree model that incorporated the final OS and toxicity
data (improvement of 3.9 months and fistula rate of 8.6 %)
showed the cost of the addition of bevacizumab was
$53,784 compared to $5688 for the chemotherapy alone
arm. Thus, the addition of bevacizumab represents an in-
crease of 13.2 times the cost for chemotherapy alone,
adding $73,791 per 3.5 months of life gained and an incre-
mental ICER of $21,083 per month of added life, mostly
due to the cost of bevacizumab rather than related with
the management of related toxicity [67]. Further explora-
tory analysis also suggested that adding Bevacizumab
would become cost-effective, with a significant decline in
the ICER, by either reducing the dose of bevacizumab
from 15 to 7.5 mg/kg, or diminishing the costs of bevaci-
zumab. Whether the benefit conferred by bevacizumab is
worthwhile or not from a cost-effectiveness perspective,
remains a societal and clinical dilemma. Further cost-
effective analyses based on real world experience, are war-
ranted. In addition the introduction of generic drugs
into the market may in time reduce the cost of target-
ing angiogenesis using this approach. However, this will
not remove the need to advocate on a global level for
accessible health care for our most economically vul-
nerable patient populations.
Summary and future directions
Angiogenesis is central to cervical cancer development
and progression. Publication of GOG 240 showing a sig-
nificant improvement in OS, PFS and ORR, without a
concomitant deterioration of HRQoL, demonstrated proof
of concept concerning integration of anti-angiogenesis
therapy for advanced cervical cancer patients, and rep-
resents a practice-changing clinical trial. The signifi-
cance of 3.7 months improvement in OS is most clear
when placed in context with prior clinical trials in this
setting (Fig. 4) [57, 68–71], (Table 1) [5, 6, 57, 70, 71].
Targeting angiogenesis is therefore a successful strategy
that should be further investigated in the next gener-
ation of clinical trials.
Several questions remain around optimal use of bevaci-
zumab. The JGOG 0505 clinical trial [6] established non-
inferiority of the better tolerated combination of carbo-
platin and paclitaxel compared to cisplatin-paclitaxel.
Extrapolating from other gynecologic cancers, bevaci-
zumab should be safe in combination with this regimen
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in women with cervical cancer, however its efficacy has
not been evaluated in a prospective randomized trial. In
addition, extrapolating from ovarian cancer, in the real
world setting there may be a role for continuing bevaci-
zumab alone following discontinuation of chemotherapy
especially given the potential improvement in quality of
life from discontinuing cytotoxic agents. More data is re-
quired in order to endorse this approach.
Evidence from the GOG 109 [5] and a number of other
studies showed that improved oxygenation and tumors
with higher MVD can lead to better outcomes with che-
moradiotherapy. The combination of an anti-angiogenic
agent, that promotes vascular normalization and improved
oxygenation combined with multimodality therapy could
potentially lead to better outcomes. However, data con-
cerning anti-angiogenic agent/radiotherapy combinations
in other tumor types suggest increased risk of fistula
formation [72], already a concern in women receiving bev-
acizumab in recurrent and metastatic disease. Radiation
Therapy Oncology Group (RTOG) 1704 evaluated the
safety and toxicity profile of adding bevacizumab (10 mg/
kg every 2 weeks) for three cycles to pelvic chemoradio-
therapy and brachytherapy. In 49 untreated patients with
locally advanced cervical cancer (stage IB–IIIB), with a
median follow-up of 3.8 years, the 3-year OS was 81.3 %
(95 % [CI], 67.2–89.8 %) and the 3-year locoregional
Fig. 4 Improvement in overall survival in advanced cervical cancer. GOG phase 3 trial experiences. Abbreviations: Bev: bevacizumab; Cis: cisplatin;
Ctx: chemotherapy; Ifo: ifosfomide; OS: overall survival; Pac, paclitaxel; Topo: topotecan
Table 1 Comparison of GOG phases 3 randomized clinical trials for women with recurrent or advanced cervical cancer. GOG
Protocols 169, 179, 204, 240 and JGOG 0505
GOG 169 [70] GOG 179 [71] GOG 204 [5] GOG 240 [57] JGOG 0505 [6]








IVB, recurrent, or persistent
SCC, ACA, or ASC
IVB, recurrent, or persistent
SCC, ACA, or ASC
IVB, recurrent, or persistent SCC,
ACA, or ASC
N 264 293 513 452 253
PS 0–2 0–2 0–1 0–1 0–2
ORR 19 vs 36 % 13 vs 27 % 29.1 vs 23.4 vs 22.3 vs 25.9 % 36 vs 48 % -
PFS 2.8 vs 4.8 mo 2.9 vs 4.6 mo 5.8 vs 4.6 vs 4.7 vs 3.9 mo 5.9 vs 8.2 mo 6.9 vs 6.21
P value <001 NS .06 vs .04 vs .19 .002 .004
OS 8.8 vs 9.7 mo 6.5 vs 9.4 mo 12.8 vs 10.2 vs 10.3 vs 9.9 mo 13.3 vs 17 mo 18.3 vs 17.5 mo
P value NS .021 .71 vs .90 vs .89 .004 .032
JGOG Japanese Gynecologic oncology group; Cis cisplatin; Pac paclitaxel; Topo topotecan; GC gemcitabine; VR vinorelbine, CB carboplatin; SCC squamous cell
carcinoma; ACA adenocarcinoma; ASC adenosquamous carcinoma; N numbers; PS performance status; ORR overall response rate; HR hazard ratio; mo months;
PFS progression free survival; NS non significance; OS overall survival
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failure was 23.2 %. These outcomes compare favorably
with historical reports. In addition, the combination was
associated with minimal protocol-defined toxicity, the
most common toxicity being myelosuppression. Of note,
there were no grade 4 gastrointestinal toxicities or gastro-
intestinal fistulas or perforations [73].
Moving beyond bevacizumab, exploration of novel
anti-angiogenic agents targeting parallel angiogenesis re-
lated pathways are being undertaken and considered in
women with cervical cancer. Single agent, orally admin-
istered, multi-TKIs, pazopanib (VEGFR 1, 2, and 3;
PDGFR-α and β; and c-KIT inhibitor) and sunitinib
(VEGFR 1, 2 and 3; PDGFR, c-KIT, and FLT3 inhibitor)
have been investigated. Sunitinib, tested in a phase II
clinical trial in patients with unresectable, locally ad-
vanced or metastatic cervical carcinoma, was associated
with an unacceptably high (26 %) rate of fistula formation
combined with only modest activity (no documented ob-
jective responses and median time to progression of
3.5 months) therefore further investigation was not
warranted [74]. In a second, larger phase II study, 230
patients, with stage IVb persistent/recurrent cervical
carcinoma not amenable to curative therapy and at
least one prior regimen in the metastatic setting, were
randomly assigned to one of three arms: pazopanib
alone, lapatinib (a TKI targeting EGFR and HER2/neu)
alone, or a combination of the two agents. Pazopanib
improved PFS (HR 0.66; 90 % CI, 0.48 to 0.91; p =
0.013) and OS (HR 0.67; 90 % CI, 0.46 to 0.99; p =
0.045) compared with lapatinib alone. Median OS was
50.7 weeks compared with 39.1 weeks for pazopanib
and lapatinib, respectively. Pazopanib alone was well
tolerated, but the combination of the two drugs lacked
effıcacy and importantly, the combination arm was
terminated at the planned interim analysis for futility
due to the significant association with more serious
adverse events [75]. Recently, the CIRCCa trial pre-
sented in the 2014 ESMO Congress [76] evaluated
cediranib (AZD2171), a selective, orally bioavailable
TKI of VEGFR-1, 2, and 3, in 69 women with primary
metastatic or relapsed cervical cancer. In the CIRCCa trial,
patients were randomized (1:1) to receive carboplatin,
tri-weekly paclitaxel, for a maximum of 6 cycles plus
cediranib (20 mg/day) or placebo concurrently with
chemotherapy, and later as maintenance therapy until
progression. The addition of cediranib improved me-
dian PFS by 5 weeks (8.8 vs 7.5 months; p = .046) and
response rate by 24 % (p = .03). However, as CIRCCa
closed prematurely owing to the cessation of commer-
cial production of cediranib, the statistical analysis of
the difference in median OS between the two groups
was underpowered for comparison (59 vs. 63 weeks;
HR, 0.93; 80 % CI, 0.64 to 1.36; p = 0.401). However,
the addition of cediranib significantly increased the rate
of diarrhea grades 2–4 (50 % compared with 18 % in the
placebo group (p = .005) and hypertension (34 v 12 %,
p = .038, respectively). Brivanib, another TKI which targets
VEGFR2 and FGFR-1, is currently being evaluated in a
phase II study (NCT01267253) conducted by the GOG.
In addition, non-VEGF-dependent therapeutic ap-
proaches, including angiopoietin inhibitors, involve other
classes of potentially attractive anti-angiogenic drugs and
are under investigation in other tumor types. These
should also be explored in cervical cancer patients. Fur-
thermore, given that Ang-2 promotes the proangiogenic
action of VEGF, the inhibition of Ang-2 and VEGF to-
gether could have complementary actions, thus, the com-
bination of an angiopoietin inhibitor, such as Trebananib
(AMG386) and an agent such as bevacizumab could be
more active than either agent alone. Combining anti-
angiogenic agents with drugs which target the PI3K/AKT/
mTOR pathway may also offer an unique treatment op-
portunity. Finally, the role of immunotherapy in the treat-
ment of cervical cancer is under investigation; potentially
combining this approach with an anti-angiogenic agent
may represent a novel therapeutic opportunity for this
patient population.
As more data emerge about the genomic landscape of
cervical cancer and its “potentially druggable” mutations
rational combinations with anti-angiogenic agents will po-
tentially be identified. However, as with all rare cancers, it
is vital that any studies undertaken have a strong under-
lying rationale and that they are designed to maximize the
biological information we can learn from them. Clearly
the way forward to improve outcome for advanced cer-
vical cancer is to reduce the rate of recurrence. We have
reached the tolerance of the combination of chemother-
apy with radiotherapy in the treatment of locally advanced
cervical cancer and the coming generation of trials need
to explore the role of targeted therapy in combination
with chemoradiotherapy in this setting.
Conclusions
Despite the introduction of screening and vaccination pro-
grams cervical cancer remains a significant health prob-
lem. The results from the GOG protocol 240 and the FDA
approval of bevacizumab in combination with chemother-
apy for the treatment of women with advanced stage, per-
sistent, or recurrent cervical cancer has established the
role for new target therapies in a population with his-
torically limited options. However in order to optimize
the use of this agent we need to learn more about pa-
tients at risk of toxicity and explore opportunities for
developing predictive biomarkers. Moving forward
there is a very strong rationale for further exploration
of angiogenesis pathways alone and in combination in
cervical cancer. However, globally we need to advocate
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for affordable and accessible therapeutic options for women
affected by this disease.
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